GSK Shingrix Shingles Vaccine Could Get CDC Panel Nod For Use In Immunocompromised Adults

 
• By Brenda Sandburg

Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.

Shingrix
GlaxoSmithKline moves to expand Shingrix vaccine for use in immunocompromised adults • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers